Question 1

What are the two main pharmacodynamic methods used to measure bioavailability?

Accepted Answer

The two main pharmacodynamic methods are acute pharmacological response and therapeutic response. The acute pharmacological response method measures direct drug effects, such as ECG or pupil diameter changes, over time. The therapeutic response method observes clinical outcomes in patients with the targeted disease. Each approach offers distinct advantages for assessing how drug formulations affect physiological processes.

Question 2

How does the acute pharmacological response method estimate bioavailability?

Accepted Answer

The acute pharmacological response method plots drug effects over at least three biological half-lives to construct an effect-time curve. This curve enables calculation of the area under the curve (AUC), a key parameter for assessing bioavailability. The method directly correlates measurable physiological responses to the drug's time course in the body, providing precise quantification under controlled conditions.

Question 3

What factors can compromise the correlation between drug response and concentration in pharmacodynamic methods?

Accepted Answer

Drug formulations and metabolic conversion of drugs into active metabolites can weaken the correlation between measured response and available drug concentration. These factors introduce variability that complicates the direct association between what is observed physiologically and the actual drug concentration present. This compromised correlation affects the accuracy of bioavailability measurements using pharmacodynamic approaches.

Question 4

Why is quantifying therapeutic response challenging in bioavailability studies?

Accepted Answer

Quantifying therapeutic response is difficult because patient response varies widely, disease progression differs among individuals, and concurrent medications complicate measurements. Drug-drug interactions in patients on multiple medications can skew results, making it hard to isolate the specific impact of the drug under study. These variables make direct comparison of bioavailability between different drug formulations problematic in real-world clinical settings.

Question 5

How do drug-drug interactions affect pharmacodynamic bioavailability measurements?

Accepted Answer

Drug-drug interactions in patients taking multiple medications can interfere with bioavailability measurements by skewing observed therapeutic responses. These interactions complicate the ability to accurately assess the specific drug's effect on physiological processes. When patients are on concurrent medications, isolating the contribution of the test drug to the overall clinical response becomes significantly more difficult.

Question 6

What is the role of the effect-time curve in acute pharmacological response assessment?

Accepted Answer

The effect-time curve is constructed by plotting drug effects over at least three biological half-lives and serves as the foundation for calculating area under the curve (AUC). AUC is essential for determining bioavailability accurately. This graphical representation allows researchers to visualize the relationship between drug concentration and physiological response over time, enabling precise bioavailability quantification.

Question 7

How does the therapeutic response method differ from the acute pharmacological response method?

Accepted Answer

The therapeutic response method administers drug formulations to patients with the targeted disease and observes real-world clinical outcomes, whereas the acute pharmacological response method measures direct physiological effects in controlled settings. The therapeutic approach reflects actual patient populations but struggles with response quantitation and variability. The acute method offers precision but may not capture complex clinical scenarios involving bioavailability enhancement determination and conceptual approaches.

Измерение биодоступности: фармакодинамические методы